LETTERS TO THE EDITOR

Physostigmine as treatment for severe CNS anticholinergic toxicity

EDITOR,—We report the successful use of physostigmine to treat central anticholinergic toxicity: a use described before but rarely seen.1 We treated a patient admitted after an overdose of amisulpride and procyclidine (not his own medication). He became extremely agitated and was treated with intravenous benzodiazepines (total quantity in 26 hours equivalent to 125 mg diazepam) but remained agitated. Because of the risks of serious injury if his agitation was untreated and of further benzodiazepine use outside a critical care area (the ward to which he was admitted has a patient:nurse ratio of 8:1), he was treated with physostigmine (total quantity in 26 hours equivalent to 125 mg diazepam) but remained agitated again and his confusion and dramatically followed by a period of coma. This was immediately and dramatically followed by a period of complete lucidity lasting 90 minutes. He did not become agitated again and his confusion resolved fully after a further 16 hours. Referral to an ICU was considered but it was felt that the risks of paralysation, intubation and ventilation (and the possible need for interhospital transfer) outweighed those associated with physostigmine treatment. This latter option had the advantage of therapeutic and diagnostic potential. Physostigmine is an antimuscarinic drug with a half life of 8 to 16 hours. When taken in overdose the features of anticholinergic toxicity may be delayed.2 It has been recorded that physical activity may reverse this feature.2 Physostigmine is a tertiary ammonium compound that reverses anticholinergic effect via acetylcholynesterase inhibition. Uniquely, for this class, it crosses the blood-brain barrier. It has a rapid onset of effect and duration of action of one to two hours.3 We do not propose that physostigmine be routinely used to treat changed mental status after poisoning. We do, believe, however, that it has a very specific role in the treatment of patients with persisting central anticholinergic toxicity despite sedation with benzodiazepines.

R TEOH
A-V PAGE
R HARDERN
Acute Medical Assessment Area, The General Infirmary, Leeds LS1 3EX, UK

Correspondence to: Dr Hardern (rhardern@uhl.northy.nhs.uk)


Pain in young children attending the accident and emergency department

EDITOR,—We read with interest the article by Macarthy et al.4 We too have experienced difficulties assessing and scoring children’s pain in the accident and emergency (A&E) setting. We feel that while subjective assessment has been shown to be the gold standard of pain assessment in some settings, for example, postoperative pain, the unexpected nature and anxiety associated with the attendance at the A&E department makes this type of scoring invalid. We have been working on developing an observational score for the assessment of pain in children presenting to the A&E department. We know from experience of auditing analgesic use in A&E that children who have a pain score allocated receive more analgesia in a more timely fashion than those who do not. Our pain score is loosely based on both the TPSS and CHEOPS’ score and relies on observations of various parameters in five categories (1) cry/vocal expression, (2) colour, (3) facial expression, (4) posture, (5) movement. Each score receives a value of 0, 1 or 2 to give a maximum total of 10 (similar to the mechanism of an Apgar score).

This score has been validated by medical students (Davis and Rostron) in the department and has shown to have good inter-rater reliability (Spearman’s rank correlation 0.82) and to have also significant constructive validity when compared with patients who presented with the same conditions. We feel that this score can be extended from the age of one year right through the paediatric population and not be just restricted to under fives, as we have experienced problems with subjective pain scoring in all age groups presenting to the department.

We endorse the suggestion that exploration of such pain scores in the A&E department should be actively pursued and intend to further validate our Alder Hey score against the modified TPSS as the author suggests.

BRIAR STEWART
A&E Paediatric Pain Group, Alder Hey Children’s Hospital, Eaton Road, Liverpool L12 2AP UK (Briar.Stewart@RLCH-TR.NWEST.NHS.UK)


Emergency medicine or accident and emergency?

EDITOR,—What is emergency medicine? Is it a subspecialty of general medicine? If this were to happen, we would lose the title and the specialty. We believe that it is now time for our specialty to adopt the name emergency medicine, to bring us in line with our colleagues in the USA, Canada, Australia, New Zealand and the Far East. If we do not, we are in danger of losing the title altogether to a subspeciality of general medicine. If this were to happen, we would be stuck with “A&E”, which, along with its predecessor “casualty”, belongs firmly in the last millennium.

IAN K DUKES
Emergency Department, Russells Hall Hospital, Dudley, West Midlands WV1 2HQ, UK (ian.dukes@dudleygoh-tr.nwmad.nhs.uk)


Intranasal diamorphine in adults

EDITOR,—We would like to describe a patient who benefited from intranasal diamorphine administration. This route has become an acceptable way of providing analgesia for children in severe pain. We believe it is also an acceptable and potentially important route for adults. It is rapidly absorbed from the venous plexi of the nasal mucosa and provides less variable pain relief than rectal or oral routes. Its aqueous solubility allows the use of small volumes.

We recently used intranasal diamorphine as pain relief in a 57 year old woman. This woman suffered from chronic renal failure, and underwent frequent dialysis. She had fallen onto her right hand. Her right elbow was tender, swollen and deformed. She was supporting this elbow with her uninjured forearm. This combined with an arteriovenous shunt in the left arm made venous access difficult. She was crying out in pain and severely distressed. To allow immobilisation and investigation she was given intranasal diamorphine, at a dose of 0.1 mg/kg. This gave immediate pain relief.

Ian Dukes
R Hardern


Intranasal diamorphine in adults

EDITOR,—We would like to describe a patient who benefited from intranasal diamorphine administration. This route has become an acceptable way of providing analgesia for children in severe pain. We believe it is also an acceptable and potentially important route for adults. It is rapidly absorbed from the venous plexii of the nasal mucosa and provides less variable pain relief than rectal or oral routes. Its aqueous solubility allows the use of small volumes.

We recently used intranasal diamorphine as pain relief in a 57 year old woman. This woman suffered from chronic renal failure, and underwent frequent dialysis. She had fallen onto her right hand. Her right elbow was tender, swollen and deformed. She was supporting this elbow with her uninjured forearm. This combined with an arteriovenous shunt in the left arm made venous access difficult. She was crying out in pain and severely distressed. To allow immobilisation and investigation she was given intranasal diamorphine, at a dose of 0.1 mg/kg. This gave immediate pain relief.
revealed a displaced four part supracondylar fracture of the right humerus with an intra-articular component.

Although the oral or intravenous routes remain the most favoured for analgesia, it is our experience that they are not always available. The oral route may be inaccessible, for example, in a hard collar or may take longer to work because of delayed gastric emptying. Intravenous and intramuscular routes are alternatives but a patient may refuse such analgesia because of a dislike of injections. The intramuscular route also has delayed action. The rectal route can be embarrassing and uncomfortable. Rapid analgesia may be necessary and the intranasal route provides this when intravenous access cannot be secured or is not strictly necessary.

We have used intranasal diamorphine on several occasions. During its use we monitor vital signs. Pain scores or direct questioning measures its efficacy. We believe that a prospective study of its use would permit identification of potential side effects or complications. It is our experience that these do not occur. Our experience is insufficient to identify the cause of nausea and vomiting which would be a significant problem.

We feel it is an important adjunct in certain clinical situations and a valuable addition to pain management.

The role of non-invasive ventilation in the emergency department

Editor,—Anthony Cross highlighted the effectiveness of non-invasive ventilation (NIV) in the emergency department in his review.1 As he concluded, studies certainly indicate that this treatment is beneficial in the treatment of acute exacerbation of chronic obstructive airways disease—with regard to the need for intubation, length of hospital stay and mortality.

The evidence for the use of NIV in the treatment of acute pulmonary oedema also exists, and is stronger than Dr Cross indicated. In addition to the three randomised controlled trials comparing chronic positive airway pressure (CPAP) with standard treatment of acute pulmonary oedema identified in the review, there also exists an article by Takeda et al from Tokyo.2 If the results of this study are pooled with the three reviewed by Cross, the overall risk reduction for mortality becomes 13.8% (95% CI 24.2 to 3.3%). The interesting thing about this finding is that the confidence interval does not cross zero.

This is the first time that pooled results have shown that CPAP treatment for heart failure, in addition to decreasing intubation rates, also decreases mortality—at least in the short-term (only two of the studies included long term follow up). There is also evidence that CPAP treatment benefits are greater in those with increasing severe pulmonary oedema.

There remains a need for a large prospective randomised controlled trial into the effectiveness of NIV compared with standard treatment of acute pulmonary oedema. If the results confirm the trends suggested in the available smaller studies, it should be sufficient to encourage our current treatment practice in UK emergency departments regarding acute pulmonary oedema. Admissions and death attributable to heart failure, unlike those attributable to the underlying disease, are predicted to increase.3 CPAP has been shown to be effective in reducing the number of these patients intubated, admitted to intensive care units or dying. Personally, I believe that there already exists an argument for the acquisition and use of CPAP/BagPap machines to treat acute pulmonary oedema in all emergency departments in the UK.

JOHN WRIGHT
Department of Accident and Emergency, Glasgow Royal Infirmary, Castle Street, Glasgow G4 0SF, UK


Editor,—We read with interest the review by Cross of the use of non-invasive ventilation (NIV) in the emergency department.1 We have appraised the evidence concerning the effectiveness of NIV in acute respiratory failure and found further evidence that both supports its use and highlights current controversies.

Although Cross comments on individual studies he does not mention the meta-analysis of trials using NIV in patients with acute respiratory failure.2 By combining the data in these trials the results achieve significance. Patients with chronic obstructive pulmonary disease (COPD) treated with NIV had reduced intubation rates with a number needed to treat (NNT) of three and reduced mortality with an NNT of five.

Further to this, the three trials of continuous positive airway pressure (CPAP) for the treatment of left ventricular failure (LVF), quoted by Cross, have been the subject of a systematic review.3 This combined the data and found a significant reduction in intubation rates for those receiving CPAP (NNT=4) and a non-significant trend towards decreased mortality.

There are however issues that have not yet been resolved. The one trial comparing CPAP with bi-level positive airway pressure (BiPAP) in patients with LVF4 was terminated early because of a high rate of myocardial infarction in the BiPAP group. The BiPAP group contained more patients with chest pain and known coronary artery disease. They also had higher mean creatinine kinase, and lower mean pH and Pao, at enrolment. As Cross reports, these differences between the two groups did not achieve statistical significance, but there was a trend towards worse baseline variables in the BiPAP group. With only 27 patients in this study the possibility of a type 2 error also exists. Further trials are needed to determine the role of BiPAP in the treatment of LVF.

Two of the three studies of CPAP in LVF excluded hypotensive patients. CPAP may increase cardiac output in patients with cardiac failure,5 and further study is needed to confirm its safety in these patients.

In our department we treat patients with respiratory distress using CPAP for LVF and BiPAP for exacerbations of COPD. Patients who are unable to cooperate or require immediate intubation are excluded. With the use of fully portable equipment NIV is a simple technique, which has the potential to benefit many emergency department patients, and we welcome the attention drawn to this by the review article.

JASON LOUIS MAELE YOUNG
Frenchay Hospital, Bristol BS16 1LE, UK

trials in which the intubation rate for the controls is usually very high (up to 74% in studies of COAD patients' and up to 60% in those with patients presenting with acute pulmonary oedema). It is almost inevitable that NIV will reduce the intubation rate when the rate is already so high in the controls. In our audit in A&E departments in Leeds, only 11% of severe acute pulmonary oedema patients (respiratory rate >23/min and pH <7.35) were intubated after the usual therapy for this condition. It is much less likely that NIV, in the A&E department, would reduce this low intubation rate significantly.

Cross also suggests that “early intervention [with NIV] will avoid the risks and complications of endotracheal intubation.” There is no doubt that the complication rate has been shown to be reduced by NIV in published studies, but in others a non-significant trend towards increased mortality in those treated with NIV has been shown and attributed to delays in intubation. It is important, therefore, to point out that NIV is not a substitute for intubation but may delay or prevent it becoming necessary in a carefully selected group of patients.

Two other points not discussed in the review are also important. Firstly, like everything else in A&E practice, there are training issues. Just because a patient who has been started on NIV in the A&E department. Some patients (particularly those with COAD) will have a prolonged requirement for NIV and it is, therefore, important to consider investing in a NIV machine, which can run from a battery.

In summary, most patients presenting to A&E with respiratory distress do not need ventilatory support. For those that do, endotracheal intubation and mechanical ventilation remains the gold standard. For a small group of patients with chronic lung disease needing urgent ventilatory support, NIV may be first line treatment. Chronic positive airway pressure undoubtedly has a role in patients with acute pulmonary oedema.

S D CRANE
A J GRAY
Accident and Emergency Department, St James’ University Hospital, Leeds LS9 7TB, UK
M W ELLIOTT
Consultant Respiratory Physician, St James’ University Hospital

You can’t anaesthetise patients—you are not employed as an anaesthetist

Editor— I would like to highlight an example of “specialty specific problem” and how the problem may be tackled. Although I was an anaesthetist for over three years and possess the anaesthetic fellowship, I have come into criticism from anaesthetists for intubating patients using anaesthetic drugs in my role as Specialist Registrar in Emergency Medicine (year 5). The first time it happened I ignored the criticism, but it has occurred since in different English hospitals. There are several issues arising out of this.

(1) There is a need to inform anaesthetic colleagues that not only is anaesthesia a core secondment but specialist registrars are keen to put the skills into practice.

(2) There is a need for individual clinicians to audit their practice of intubating patients in the emergency department. My personal logbook (kept on Microsoft Access) covers patient name, date, indication for intubation, drugs administered, morbidity and mortality. Thus it covers not only the “flat overdose patient” or “coma ?subarachnoid” but also patients who arrive in cardiac arrest un-intubated.

(3) There is a risk management need, as a specialty, to nationally audit morbidity and mortality in relation to patients being intubated by emergency department staff. In addition to the criteria above, timeliness and appropriateness of intubation should be considered.

So what if we do not audit this particular area of activity? When the inevitable disaster happens the clinical governance committee of the hospital may judge rapid sequence induction and intubation to be a procedure for the elite few doctors who satisfy the following criteria: confident, competent, qualified and employed as anaesthetists.

MARK F NICOL
Correspondence to: Dr Nicol, 7 Burchill Close, Clutton, Bristol BS9 3PR (marknicol@hotmail.com)

BOOK REVIEWS


Seventy five years ago an American advertising executive wrote that “one picture is worth ten thousand words”. The aphorism holds particularly true for busy junior doctors preparing for examinations. This little book offers 150 pictures; clinical images, radiographs, tables of monitored data and diagrams to explain basic principles. The book is aimed at medical students, critical care trainees and surgeons in training. However, the topics covered are not exclusive to intensive care medicine and many conditions relevant to the emergency physician are included. Trauma, toxicology and resuscitation topics are among the chapters that focus on the psychological effects of trauma are perhaps the most sobering, but other elements of care that are important to the patient are also covered—e.g. elimination of tissue viability, available data and mouth care to name but a few. But don’t be fooled into thinking that this is purely a nursing textbook—the contributors come from all disciplines involved in the care and rehabilitation of the trauma patient, with many team members writing their own chapters in the book. The book is made complete with considerations in the final section of the actual service delivery and the staff that work within the service.
This book has succeeded in making me rethink my often narrow approach to trauma care, and I have set myself the task of recommending it to all the areas within the hospital that have contact with “trauma patients”. I hope that if I ever have the misfortune to be seriously injured I am looked after by people who have a similar patient orientated approach.

CAROLINE WILLIAMS
Senior Sister, Accident and Emergency,
West Wales General Hospital, Carmarthen, UK

Books received

CORRECTION
Mr R A Simpson should have been acknowledged as a scan coordinator for the Journal scan that appeared in the January 2001 issue of the journal (2001;18:71–3).

NOTICES
15th Annual Trauma Anesthesia and Critical Care Symposium
23–25 May 2002, Stavanger, Norway
Further details: e-mail: congress-secretary@traumacare2002.com, web site: www-traumacare2002.com, tel: +47 51 74 91 02, fax: +47 51 74 70 02.

18th Annual Scientific Meeting of the Australasian College for Emergency Medicine, incorporating the 22nd Annual Scientific Meeting of the Australasian Society for Emergency Medicine
30 September to 4 October 2001, Hobart, Tasmania
Further details: the programme of the meeting and details of how to register are at the web site www.cdesign.com.au/acem2001

World Congress on Drowning
26–28 June 2002, Amsterdam, the Netherlands
Further details: Congress Secretariat World Congress on Drowning 2002, Consumer Safety Institute, PO Box 75 169, 1070 Amsterdam, the Netherlands (tel: +31 20 511 45 14, fax: +31 20 511 45 10, e-mail: Secretariat@drowning.nl, web site: www.drowning.nl).
Pain in young children attending the accident and emergency department

Briar Stewart

*Emerg Med J* 2001 18: 412
doi: 10.1136/emj.18.5.412-a

Updated information and services can be found at:
http://emj.bmj.com/content/18/5/412.2

These include:

**References**
This article cites 2 articles, 1 of which you can access for free at:
http://emj.bmj.com/content/18/5/412.2#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/